#1 Clinical Trials Search in Europe

Talazoparib

Talazoparib is an innovative drug being studied in clinical trials for the treatment of advanced breast cancer, particularly in patients with BRCA mutations. This article explores the use of talazoparib in various clinical trials, its potential benefits, and important information for patients considering this treatment option.

Table of Contents

What is Talazoparib?

Talazoparib is a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as PARP inhibitors, which work by interfering with cancer cells’ ability to repair their DNA, ultimately leading to their death. Talazoparib is also known by other names, including MDV3800 and BMN673[7][8].

This drug is primarily used in patients with advanced solid tumors, particularly in those with specific genetic mutations that make their cancer cells more susceptible to PARP inhibition[1].

How Talazoparib Works

Talazoparib works by inhibiting an enzyme called poly (ADP-ribose) polymerase (PARP). PARP is involved in repairing damaged DNA in cells. By blocking this enzyme, talazoparib prevents cancer cells from repairing their DNA, which leads to the accumulation of DNA damage and eventually causes the cancer cells to die[2].

This mechanism is particularly effective in cancer cells with mutations in genes like BRCA1 or BRCA2, which are also involved in DNA repair. When both PARP and these genes are not functioning, it becomes very difficult for cancer cells to survive, a concept known as “synthetic lethality”[3].

Conditions Treated with Talazoparib

Talazoparib is used to treat several types of advanced solid tumors, including:

  • Breast cancer: Particularly in patients with HER2-negative breast cancer and mutations in the BRCA1 or BRCA2 genes[3]
  • Ovarian cancer: Including fallopian tube and primary peritoneal cancers[4]
  • Prostate cancer[5]
  • Non-small cell lung cancer (NSCLC)[5]
  • Pancreatic cancer[5]
  • Colorectal cancer[5]

It’s important to note that talazoparib is often used in patients whose cancer has advanced or spread to other parts of the body (metastasized) and who have specific genetic mutations that make their cancer more likely to respond to this treatment[1].

How Talazoparib is Administered

Talazoparib is taken orally, usually once daily. The typical dose is 1 mg per day, but this can vary depending on the patient’s condition and response to treatment[1]. It’s important to take talazoparib exactly as prescribed by your doctor.

The medication can be taken with or without food[2]. Each treatment cycle typically lasts 28 days, and treatment continues until the disease progresses or unacceptable side effects occur[1].

Efficacy of Talazoparib

Clinical trials have shown promising results for talazoparib in treating various types of cancer:

  • In patients with advanced breast cancer and BRCA mutations, talazoparib has demonstrated significant tumor shrinkage and improved progression-free survival[3].
  • Studies have shown that a significant percentage of patients achieve an objective response (meaning their tumors shrink or disappear) when treated with talazoparib[2].
  • The drug has also shown potential in treating other types of solid tumors, especially in patients with specific genetic mutations[1].

It’s important to note that the effectiveness of talazoparib can vary depending on the individual patient and the specific characteristics of their cancer.

Side Effects and Safety Considerations

Like all medications, talazoparib can cause side effects. Some of the most common side effects include:

  • Fatigue: Feeling very tired or weak
  • Anemia: Low red blood cell count, which can cause tiredness and shortness of breath
  • Nausea and vomiting
  • Decreased appetite
  • Diarrhea
  • Headache
  • Low white blood cell count: This can increase the risk of infections
  • Low platelet count: This can increase the risk of bleeding or bruising

More serious side effects, although less common, can include severe bone marrow problems, such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)[6].

It’s crucial to report any side effects to your healthcare provider. They may adjust your dose or provide treatments to manage side effects[2].

Use in Special Populations

Research has been conducted to understand how talazoparib affects patients with various health conditions:

  • Patients with kidney problems: Studies have shown that talazoparib can be used in patients with varying degrees of kidney function, but dose adjustments may be necessary[7].
  • Patients with liver problems: Similar studies have been conducted in patients with liver impairment to determine appropriate dosing[8].

Always inform your doctor about any existing health conditions you have, as this may affect how talazoparib is prescribed or monitored.

Ongoing Research and Future Directions

Researchers continue to study talazoparib to understand its full potential in cancer treatment. Some areas of ongoing research include:

  • Using talazoparib in combination with other cancer treatments to potentially enhance its effectiveness[2].
  • Exploring its use in earlier stages of cancer or as a preventive treatment in high-risk individuals[3].
  • Investigating its effectiveness in other types of cancers or in patients with different genetic profiles[1].

As research progresses, our understanding of how best to use talazoparib in cancer treatment continues to evolve. Your oncologist can provide the most up-to-date information about how this medication might fit into your specific treatment plan.

Aspect Details
Drug Name Talazoparib (also known as BMN 673 or Talzenna)
Drug Class PARP (poly ADP-ribose polymerase) inhibitor
Primary Indication HER2-negative advanced or metastatic breast cancer with germline BRCA mutations
Administration Oral, typically 1 mg once daily
Key Clinical Trials NCT03990896, NCT05288127, NCT03343054, NCT01989546
Primary Outcomes Progression-free survival, Overall response rate
Common Side Effects Fatigue, anemia, nausea, neutropenia, thrombocytopenia
Ongoing Research Efficacy in other solid tumors, combination therapies, biomarker studies

FAQ

  • What is talazoparib? Talazoparib is a PARP (poly ADP-ribose polymerase) inhibitor, a type of targeted therapy drug used to treat certain types of breast cancer. It works by blocking the PARP enzyme, which helps repair damaged DNA in cancer cells, potentially making it more difficult for these cells to survive and multiply.
  • Who might benefit from talazoparib treatment? Talazoparib is primarily being studied in patients with HER2-negative advanced or metastatic breast cancer who have inherited BRCA1 or BRCA2 gene mutations. Some trials are also exploring its use in patients with other types of advanced solid tumors or those with somatic (non-inherited) BRCA mutations.
  • How is talazoparib administered? Talazoparib is typically given as an oral medication, taken once daily. The usual dose is 1 mg per day, but this may vary depending on the specific trial and individual patient factors. It is generally taken continuously until disease progression or unacceptable side effects occur.
  • What are the potential side effects of talazoparib? Common side effects of talazoparib may include fatigue, anemia (low red blood cell count), nausea, neutropenia (low white blood cell count), thrombocytopenia (low platelet count), and hair loss. Your healthcare team will monitor you closely for these and other potential side effects during treatment.
  • How effective is talazoparib in treating breast cancer? Clinical trials have shown promising results for talazoparib in treating advanced breast cancer, particularly in patients with BRCA mutations. Some studies have demonstrated improved progression-free survival and overall response rates compared to standard chemotherapy. However, individual results may vary, and more research is ongoing to fully understand its effectiveness in different patient populations.

Ongoing Clinical Trials on Talazoparib

  • Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Finland France Germany Hungary +6

Glossary

  • PARP inhibitor: A type of targeted cancer drug that blocks the activity of poly ADP-ribose polymerase (PARP) enzymes, which help repair damaged DNA in cells. By inhibiting PARP, these drugs can make it harder for cancer cells to repair their DNA and survive.
  • BRCA mutations: Inherited changes in the BRCA1 or BRCA2 genes that increase a person's risk of developing certain cancers, including breast and ovarian cancer. These mutations can also make cancer cells more sensitive to certain treatments, such as PARP inhibitors.
  • HER2-negative breast cancer: A type of breast cancer that does not have high levels of a protein called human epidermal growth factor receptor 2 (HER2). This classification helps determine appropriate treatment options.
  • Metastatic breast cancer: Breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, lungs, liver, or brain.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening. PFS is often used as a measure of treatment effectiveness in clinical trials.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment. It includes patients with complete response (disappearance of all signs of cancer) and partial response (decrease in tumor size or extent of cancer).
  • Adverse events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure. In clinical trials, adverse events are carefully monitored to assess the safety of the treatment being studied.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or that require a reduction in dose during a clinical trial. DLTs help determine the maximum tolerated dose of a new drug.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This information helps determine appropriate dosing and potential drug interactions.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standardized set of rules used to assess how well a cancer patient responds to treatment. It is based on whether tumors shrink, stay the same, or get bigger.

References

  1. https://clinicaltrials.gov/study/NCT04635631
  2. https://clinicaltrials.gov/study/NCT03343054
  3. https://clinicaltrials.gov/study/NCT03499353
  4. https://clinicaltrials.gov/study/NCT02316834
  5. https://clinicaltrials.gov/study/NCT04672460
  6. https://clinicaltrials.gov/study/NCT02921919
  7. https://clinicaltrials.gov/study/NCT02997163
  8. https://clinicaltrials.gov/study/NCT02997176